네이처셀

007390KOSDAQ

57.4 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment14.4 / 25

Momentum13.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 11.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

NatureCell focuses on developing and selling stem cell therapies (e.g., JointStem, AstroStem), stem cell culture media, cosmetics, and beverage R&D and sales. The company is expanding its global presence through clinical trials in the U.S. and Japan, as well as a 2022 acquisition of a U.S. subsidiary. In 2024, the stem cell business accounted for approximately 68% of total revenue.

Number of Employees

83people

Average Salary

45.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-4.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.76Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼302.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 1Average Sentiment Score 57.5

Negative
네이처셀, 주주 고발로 조인트스템 공방 재점화…향후 쟁점 포인트는
주주 고발로 인해 네이처셀의 조인트스템 관련 논란이 재점화되어 부정적 영향이 예상됩니다.
Neutral
조인트스템, 한국선 막히고 미국선 신속개발…판단 엇갈린 이유
네이처셀의 조인트스템에 대한 한국과 미국 규제 당국의 판단 차이로 인해 시장 반응은 중립적이다.

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 24,700Won52-week high 34,55052-week low 16,900

1-month return5.0Point

1m +11.01% (rising)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0

Positive유상증자결정(종속회사의주요경영사항)2026-08-26
Neutral타법인주식및출자증권취득결정2026-08-26
Neutral반기보고서 (2026.06)2026-08-14